SCHEMBL57083

SCHEMBL57083

CC(C)Cc1ccc(O)c(O)c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 9/20 0.76
ALOX12 P18054 7/20 0.76
KDM4E B2RXH2 4/20 0.76
RECQL P46063 3/20 0.76
HIF1A Q16665 3/20 0.76
HSD17B10 Q99714 3/20 0.76
ALDH1A1 P00352 3/20 0.76
MEN1 O00255 2/20 0.76
ESR1 P03372 2/20 0.76
TP53 P04637 2/20 0.76
CYP3A4 P08684 2/20 0.76
HPGD P15428 2/20 0.76
MAPK1 P28482 2/20 0.76
KMT2A Q03164 2/20 0.76
TRPA1 O75762 2/20 0.76
USP2 O75604 2/20 0.76
ADORA3 P0DMS8 2/20 0.76
HTR2A P28223 2/20 0.76
PTGS2 P35354 2/20 0.76
TDP1 Q9NUW8 2/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nordihydroguaiaretic Acid SCHEMBL135976 0.86 ALOX15 (1.00) ALOX15ALOX12KDM4ERECQLHIF1A
Masoprocol SCHEMBL29355090 0.86 ALOX15 (1.00) ALOX15ALOX12KDM4ERECQLHIF1A
Masoprocol SCHEMBL3818 0.86 ALOX15 (1.00) ALOX15ALOX12KDM4ERECQLHIF1A
SCHEMBL340070 0.86 GABRA1 (0.64) ALOX15ALOX12KDM4ERECQLHIF1A
Nordihydroguaiaretic Acid SCHEMBL13906133 0.86 ALOX15 (1.00) ALOX15ALOX12KDM4ERECQLHIF1A
Nordihydroguaiaretic Acid SCHEMBL29434237 0.86 ALOX15 (1.00) ALOX15ALOX12KDM4ERECQLHIF1A
Masoprocol SCHEMBL29350884 0.86 ALOX15 (1.00) ALOX15ALOX12KDM4ERECQLHIF1A
Nordihydroguaiaretic Acid SCHEMBL29434238 0.86 ALOX15 (1.00) ALOX15ALOX12KDM4ERECQLHIF1A
SCHEMBL7935287 0.84 ALOX15 (0.73) ALOX15ALOX12KDM4ERECQLHIF1A
SCHEMBL31488529 0.84 ALOX15 (0.73) ALOX15ALOX12KDM4ERECQLHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10202474-B2 Process for producing polydienes BRIDGESTONE CORPORATION (JP) 2019-02-12 US claimed
US-20170073443-A1 PROCESS FOR PRODUCING POLYDIENES BRIDGESTONE CORPORATION (US) 2017-03-16 US claimed
CN-106413754-A Dopa decarboxylase inhibitor compositions 纽罗德姆有限公司 2017-02-15 CN claimed
CN-103257137-A Method of determining content of methyl ethyl ketone peroxide in workplace air through UV spectrophotometer PONY TESTING INTERNAT GROUP 2013-08-21 CN claimed
US-11685715-B2 Antimicrobial compounds and nanostructures THE BOEING COMPANY (US) 2023-06-27 US disclosed
US-20230183428-A1 CATECHOL FUNCTIONAL ORGANOPOLYSILOXANE, METHOD FOR PRODUCING SAME, AND POWDER TREATMENT AGENT SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-06-15 US disclosed
US-20230117680-A1 CYCLOPHILIN D INHIBITORS AND USES THEREOF THE BROAD INSTITUTE, INC. (US) 2023-04-20 US disclosed
WO-2023010282-A1 PROCESS FOR PRODUCTION OF SUBSTITUTED OR UNSUBSTITUTED CATECHOL O, O-DIACETIC ACID ESTERS RHODIA OPERATIONS (FR) 2023-02-09 WO disclosed
US-11358985-B2 Tripeptide compound, preparation method therefor, and application thereof NORTHWEST UNIVERSITY (CN) 2022-06-14 US disclosed
US-11174227-B2 Antimicrobial compounds and nanostructures THE BOEING COMPANY (US) 2021-11-16 US disclosed
US-11078233-B2 Tripeptide epoxy ketone protease inhibitors ONYX THERAPEUTICS, INC. (US) 2021-08-03 US disclosed
US-20200354404-A1 PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2020-11-12 US disclosed
EP-0261977-A2 Catechol derivatives, and preventive and remedial preparations for regressive disorders in the central nervous system MITSUI TOATSU CHEMICALS, Inc. (JP) 1988-03-30 EP disclosed
EP-0076221-B1 PROCESS FOR THE ETHERIFICATION OF PHENOLS RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1985-05-02 EP disclosed
EP-0037353-B1 PROCESS FOR THE ETHERIFICATION OF PHENOLS RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1983-06-08 EP disclosed
EP-0076221-A1 Process for the etherification of phenols RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1983-04-06 EP disclosed
EP-0046719-A1 Process for the etherification of phenols RHONE-POULENC INDUSTRIES (FR) 1982-03-03 EP disclosed
EP-0037353-A1 Process for the etherification of phenols RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1981-10-07 EP disclosed
US-4212645-A Hair dyeing composition containing an aryldiamine and a substituted catechol LEVER BROTHERS COMPANY (US) 1980-07-15 US disclosed
US-3979415-A Method of preparation of sulfonated, dialkyl-substituted benzodioxoles TEXACO INC. (US) 1976-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11685715-B2 Antimicrobial compounds and nanostructures MPO, POLI, POLN ALOX15 4036/4885ALOX12 4182/4885KDM4E 2703/4885
US-11078233-B2 Tripeptide epoxy ketone protease inhibitors PREP, CTRL, ENPEP ALOX15 446/4885ALOX12 788/4885KDM4E 353/4885
US-11358985-B2 Tripeptide compound, preparation method therefor, and application thereof VIP, PREP, ACE ALOX15 518/4885ALOX12 757/4885KDM4E 4263/4885
US-11174227-B2 Antimicrobial compounds and nanostructures MPO, POLI, POLN ALOX15 4036/4885ALOX12 4182/4885KDM4E 2703/4885
US-20230117680-A1 CYCLOPHILIN D INHIBITORS AND USES THEREOF PPID, PPIF, PPIL1 ALOX15 1176/4885ALOX12 1255/4885KDM4E 4072/4885
US-20230183428-A1 CATECHOL FUNCTIONAL ORGANOPOLYSILOXANE, METHOD FOR PRODUCING SAME, AND POWDER TREATMENT AGENT COMT, MAN2B1, FANCD2 ALOX15 2666/4885ALOX12 1787/4885KDM4E 2759/4885
US-20200354404-A1 PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF DNPEP, PEPD, ANPEP ALOX15 3191/4885ALOX12 3343/4885KDM4E 4843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.